​

Intellia Therapeutics Ownership | Who Owns Intellia Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Intellia Therapeutics Ownership Summary

Intellia Therapeutics is owned by 122.40% institutional investors, 3.86% insiders. Ark investment management is the largest institutional shareholder, holding 14.24% of NTLA shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 7.96% of its assets in Intellia Therapeutics shares.

NTLA Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockIntellia Therapeutics122.40%3.86%-26.26%
SectorHealthcare Stocks 246.48%12.12%-158.60%
IndustryBiotech Stocks 384.82%11.76%-296.58%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management16.88M14.24%$285.54M
Blackrock funding, inc. /de15.41M13.00%$260.72M
Vanguard group13.01M11.81%$116.96M
Blackrock9.60M10.05%$214.79M
State street9.23M7.79%$156.26M
D. e. shaw6.44M5.44%$109.02M
Vanguard capital management6.03M5.09%$102.00M
Two sigma investments, lp5.24M4.42%$88.58M
Fmr4.77M4.03%$80.76M
Ra capital management4.53M3.82%$76.60M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Regeneron pharmaceuticals3.70M35.35%$62.65M
Birchview capital, lp385.90K3.17%$6.78M
Contrarius investment management1.92M2.68%$42.87M
Ark investment management16.88M1.85%$285.54M
Deuterium capital management100.00K1.83%$1.69M
Contrarius group1.96M1.52%$33.08M
Orchard capital management79.50K1.31%$1.35M
Scientech research72.53K0.99%$1.23M
Iq eq fund management (ireland)777.95K0.84%$13.16M
Sector gamma as185.18K0.68%$3.13M

Top Buyers

HolderShares% AssetsChange
Ra capital management4.53M0.67%4.53M
Blackrock funding, inc. /de15.41M0.00%3.25M
Fmr4.77M0.00%2.71M
Ark investment management16.88M1.85%2.37M
State street9.23M0.00%2.31M

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---4.95M
Capital investors---3.78M
Rokos capital management llp---1.14M
Granahan investment management342.59K0.24%-571.04K
Ubs group2.15M0.00%-536.57K

New Positions

HolderShares% AssetsChangeValue
Ra capital management4.53M0.67%4.53M$76.60M
Sixth street partners management company1.21M0.00%1.21M$20.44M
Ghisallo capital management1.20M0.40%1.20M$20.30M
Baker bros. advisors lp930.23K0.08%930.23K$15.74M
Farallon capital management607.20K0.04%607.20K$10.49M

Sold Out

HolderChange
Corecap advisors-1.00
Activest wealth management-1.00
Dinuzzo private wealth-1.00
Global financial private client-1.00
Jfs wealth advisors-2.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20263509.03%145,029,74431.34%1221.18%1940.52%8126.56%
Mar 31, 2026218-31.01%72,199,779-30.72%660.74%127-22.09%42-53.33%
Dec 31, 2025221-28.25%80,835,304-22.43%730.82%102-32.45%72-10.00%
Sep 30, 20252891.05%103,222,25512.82%991.28%143-2.72%76-8.43%
Jun 30, 2025290-7.05%98,735,343-2.49%950.99%146-0.68%85-10.53%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite11.13M7.96%1.82M
ARK Innovation ETF10.00M7.14%163.64K
American Funds SMALLCAP World A3.78M3.65%3.78M
Vanguard MStar Total Stk Mkt Idx Invest4.32M3.08%18.66K
State Street® SPDR® S&P® Biotech ETF4.31M3.08%-82.45K
Vanguard Total Stock Mkt Idx Inv4.29M3.07%-18.46K
Vanguard Morn Total Stk Mkt Idx Investor4.29M3.07%-18.46K
Vanguard US Total Market Shares ETF3.17M3.06%299.88K
iShares Russell 2000 ETF3.56M2.54%-41.09K
Vanguard Small Cap Index3.16M2.25%37.85K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 02, 2026Dube Michael P VP, Chief Accounting OfficerSell$23.17K
Aug 20, 2026LEONARD JOHN M President and CEOSell$250.61K
Aug 21, 2026LEONARD JOHN M President and CEOSell$36.20K
Jul 22, 2026Dulac Edward J III EVP, Chief Financial OfficerSell$91.25K
Jul 01, 2026Dube Michael P VP, Chief Accounting OfficerSell$44.32K

Insider Transactions Trends

DateBuySell
2026 Q4-1
2026 Q3-5
2026 Q2--
2026 Q119
2025 Q4-5

NTLA Ownership FAQ

Who Owns Intellia Therapeutics?

Intellia Therapeutics shareholders are primarily institutional investors at 122.40%, followed by 3.86% insiders and -26.26% retail investors. The average institutional ownership in Intellia Therapeutics's industry, Biotech Stocks , is 384.82%, which Intellia Therapeutics falls below.

Who owns the most shares of Intellia Therapeutics?

Intellia Therapeutics’s largest shareholders are Ark investment management (16.88M shares, 14.24%), Blackrock funding, inc. /de (15.41M shares, 13.00%), and Vanguard group (13.01M shares, 11.81%). Together, they hold 39.05% of Intellia Therapeutics’s total shares outstanding.

Does Blackrock own Intellia Therapeutics?

Yes, BlackRock owns 10.05% of Intellia Therapeutics, totaling 9.6M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 214.79M$. In the last quarter, BlackRock increased its holdings by 488.34K shares, a 5.36% change.

Who is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested?

Regeneron pharmaceuticals is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested, with 35.35% of its assets in 3.7M Intellia Therapeutics shares, valued at 62.65M$.

Who is the top mutual fund holder of Intellia Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Intellia Therapeutics shares, with 7.96% of its total shares outstanding invested in 11.13M Intellia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools